From Wikidoc - Reading time: 1 min
|
WikiDoc Resources for Thorium-232 |
|
Articles |
|---|
|
Most recent articles on Thorium-232 Most cited articles on Thorium-232 |
|
Media |
|
Powerpoint slides on Thorium-232 |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Thorium-232 at Clinical Trials.gov Clinical Trials on Thorium-232 at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Thorium-232
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Thorium-232 Discussion groups on Thorium-232 Patient Handouts on Thorium-232 Directions to Hospitals Treating Thorium-232 Risk calculators and risk factors for Thorium-232
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Thorium-232 |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Thorium-232 is the primary abundant nuclide of thorium. It is a slightly unstable radionuclide that is found in the earth's crust. It is a fertile material able to absorb a neutron and undergo transmutation into a nuclide that is able to support fission (uranium-233).
In the form of Thorotrast, a thorium oxide suspension, it was used as contrast medium in early X-ray diagnostics. Thorium-232 is now classified as carcinogenic. The half-life of thorium-232 is 1.405Template:E years. Template:WH Template:WikiDoc Sources